hydroxychloroquine

P1/2, N=41, Active, not recruiting, Ravi Amaravadi, MD | Recruiting --> Active, not recruiting | N=94 --> 41 | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2027 --> Jul 2026

P2, N=7, Terminated, Northwestern University | Trial completion date: Jul 2030 --> Apr 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Oct 2025; The study was closed due to accrual.

Taken together, these findings support itraconazole as a promising candidate for further in vivo and clinical investigation in selected oral cancers, including HNSCC and OSCC. Nevertheless, the definition of clinical treatment schedules will require additional comprehensive pharmacokinetic, toxicological, and clinical studies.

P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026

P4, N=10, Not yet recruiting, University of California, San Francisco | Initiation date: Jan 2026 --> Aug 2026

P2, N=334, Recruiting, Centre Hospitalier Universitaire de Saint Etienne | Not yet recruiting --> Recruiting

In addition, to confirm the pivotal role of AuNPs in ROS generation, AuNPs-treated cells were also cultured in the presence of N-acetylcysteine (NAC; as an antioxidant agent) and hydroxychloroquine (HCQ; as an inhibitor of autophagosome formation). Our finding suggest that AuNPs-induced ROS can promote autophagy and apoptosis via mitochondrial dysfunction and regulation of the ROS/JNK signaling pathway in MCF-7 cancer cells. Thereby highlighting the potential therapeutic value of AuNPs as anticancer agents.

This review provides a systematic analysis of the clinical, biological, and histological characteristics of EF, its associated triggers, and therapeutic strategies based on a comprehensive review of reported cases. We found that poor prognostic factors include diagnostic delay (>6 months), trunk involvement, early-onset disease (<12 years), and morphea-like skin lesions.

P2, N=43, Recruiting, Northwestern University | Trial completion date: Jul 2028 --> Jul 2030 | Trial primary completion date: Jul 2026 --> Jul 2028

The GC203 regimen, combining piggyBac-mbIL-7 autologous TILs with anti-PD-1 antibody, demonstrates favorable safety and promising efficacy in heavily pretreated rOC, which supports its further development in this high-need population.

P2, N=44, Recruiting, Abramson Cancer Center at Penn Medicine | N=66 --> 44

P1, N=20, Active, not recruiting, Fox Chase Cancer Center | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Dec 2025